Leveraging biomimicry and evidence-based medicine, SolasCure is a pioneering biologics company developing its first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, which aims to accelerate debridement of chronic wounds. Through developing its innovative debridement technology, SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds in an outpatient or home setting. SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company focused on harnessing biological diversity to develop innovative solutions. SolasCure is headquartered in Cambridge, UK.
